Wafik S. El-Deiry, Director of Legorreta Cancer Center at Brown University and Chair of the WIN Consortium in Cancer Personalized Medicine, shared a post on LinkedIn:
“Great presentation about the challenges of glioblastoma in precision oncology “Precision in Neuro Oncology: Promise vs Practical Limits” by Dr. Aya El Helali at Illuminate 3.0 Oncology Town Hall in Mumbai. WIN Consortium in cancer personalized medicine Razelle Kurzrock Catherine Bresson Sewanti Limaye, MBBS, MD, MS OncoDaily Fanny Wunder
It was great to meet with her after the presentation as she spoke about ONC201 discovered in my lab 19 years ago and approved by the US FDA in August 2025 for recurrent H3K27M-mutated gliomas. She is a site PI for the Jazz Pharmaceuticals phase III ACTION trial in Hong Kong.
I invited Dr. El Helali to participate in the WIN Consortium international Molecular Tumor Board where we have quite a few presentations of complex and challenging cases of glioblastoma including with or without H3K27M mutation.”
Other articles featuring Wafik S. El-Deiry on OncoDaily.
